Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment : A case report
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved..
BACKGROUND: Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor reduction to make potential surgery possible. However, the outcomes of such surgery are unknown. We report a successful case of hepatic resection for recurrent HCC after lenvatinib treatment.
CASE SUMMARY: A 69-year-old man underwent right anterior sectionectomy for HCC in segment 8 of the liver. Ten months later, he was found to have an intrahepatic HCC recurrence that grew rapidly to 10 cm in diameter with sternal bone metastases. After confirming partial response to lenvatinib administration for 2 mo, a second hepatectomy was performed. Pathological examination showed that 80% of the tumor was necrotic. The patient did not develop any adverse effects under lenvatinib treatment. He was discharged at 25 d after surgery. Radiation therapy for bone metastases continued to be given under lenvatinib, and the patient has remained alive for 1 year after the second hepatectomy.
CONCLUSION: The prognosis of patients with recurrent HCC may be improved by liver resection combined with prior lenvatinib therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
World journal of hepatology - 12(2020), 12 vom: 27. Dez., Seite 1349-1357 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yokoo, Hideki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 15.01.2021 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4254/wjh.v12.i12.1349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320057445 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320057445 | ||
| 003 | DE-627 | ||
| 005 | 20231225172750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4254/wjh.v12.i12.1349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM320057445 | ||
| 035 | |a (NLM)33442460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yokoo, Hideki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment |b A case report |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.01.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Lenvatinib has been shown to be noninferior to sorafenib regarding prognosis and recurrence rate in patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic chemotherapy. In patients treated with lenvatinib, 40% of cases achieved sufficient tumor reduction to make potential surgery possible. However, the outcomes of such surgery are unknown. We report a successful case of hepatic resection for recurrent HCC after lenvatinib treatment | ||
| 520 | |a CASE SUMMARY: A 69-year-old man underwent right anterior sectionectomy for HCC in segment 8 of the liver. Ten months later, he was found to have an intrahepatic HCC recurrence that grew rapidly to 10 cm in diameter with sternal bone metastases. After confirming partial response to lenvatinib administration for 2 mo, a second hepatectomy was performed. Pathological examination showed that 80% of the tumor was necrotic. The patient did not develop any adverse effects under lenvatinib treatment. He was discharged at 25 d after surgery. Radiation therapy for bone metastases continued to be given under lenvatinib, and the patient has remained alive for 1 year after the second hepatectomy | ||
| 520 | |a CONCLUSION: The prognosis of patients with recurrent HCC may be improved by liver resection combined with prior lenvatinib therapy | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Case report | |
| 650 | 4 | |a Conversion to surgery | |
| 650 | 4 | |a Lenvatinib | |
| 650 | 4 | |a Molecular targeted therapy | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Recurrent hepatocellular carcinoma | |
| 700 | 1 | |a Takahashi, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Hagiwara, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Iwata, Hiroyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Yoshinori |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuno, Naoto |e verfasserin |4 aut | |
| 700 | 1 | |a Furukawa, Hiroyuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World journal of hepatology |d 2009 |g 12(2020), 12 vom: 27. Dez., Seite 1349-1357 |w (DE-627)NLM204379024 |x 1948-5182 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:12 |g day:27 |g month:12 |g pages:1349-1357 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4254/wjh.v12.i12.1349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 12 |b 27 |c 12 |h 1349-1357 | ||